Tag: InspireMD
InspireMD receives CE-mark recertification under new EU regulatory framework
InspireMD announced today that it has received CE-mark recertification under the European Union’s (EU) new Medical Device Regulation (MDR) regulatory framework for its CGuard...
InspireMD presents positive 30-day follow-up results from C-GUARDIANS clinical trial
InspireMD recently presented 30-day results from the C-GUARDIANS US investigational device exemption (IDE) clinical trial evaluating its CGuard embolic prevention stent (EPS) system for...
InspireMD announces completed enrolment in C-Guardians US IDE trial
InspireMD today announced that it has completed enrolment of its ongoing C-Guardians US Investigational Device Exemption (IDE) clinical trial, designed to support potential US...
InspireMD announces the inclusion of its CGuard carotid stent in CREST-2...
InspireMD has announced that its CGuard embolic prevention stent system (EPS) will be included as a device option for stenting in CREST-2 (Carotid revascularisation...
InspireMD report “superior clinical outcomes” for next-generation mesh-covered stents
InspireMD has released the results of a meta-analysis of four clinical studies involving dual-layered and mesh-covered stents, including the company’s MicroNet-covered stent, the CGuard...
Expanded two-year follow-up results from the PARADIGM clinical study using CGuard...
Piotr Musiałek, from the Department of Cardiac and Vascular Diseases, John Paul II Hospital, Kraków, Poland, presented the expanded 24-month follow-up results from the...
